Outset Medical (OM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: Brent D. Lang and Karen Prange, with board recommendation to vote for both nominees.
Advisory vote to approve 2025 compensation for named executive officers, recommended for approval by the board.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026, with board recommendation to vote for.
Proxy holders authorized to vote on other business that may arise at the meeting or any adjournment.
Board of directors and corporate governance
Board is presenting two nominees for election to Class III director positions at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the 2025 compensation for named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Outset Medical
- Q1 revenue fell 6% but gross margin hit 43.4% and net loss narrowed to $19.0 million.OM
Q1 20268 May 2026 - Annual meeting covers director elections, say-on-pay, auditor ratification, and governance updates.OM
Proxy filing24 Apr 2026 - 2025 revenue rose 5% to $119.5M, margins improved, and 2026 growth is guided at 5–9%.OM
Q4 202511 Feb 2026 - Revenue declined but gross margin and recurring revenue improved; 2024 outlook lowered.OM
Q2 20242 Feb 2026 - Cost reductions and margin expansion accelerate profitability as TabloCart ramps post-clearance.OM
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q3 2024 saw record recurring revenue, margin gains, and raised guidance despite ongoing restructuring.OM
Q3 202416 Jan 2026 - Innovative dialysis solutions and strong recurring revenue drive growth and industry disruption.OM
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Tablo technology drives recurring revenue and improved dialysis outcomes in acute and home markets.OM
Investor presentation14 Jan 2026 - Sales transformation, recurring revenue growth, and margin expansion set up a strong 2025.OM
Stifel 2024 Healthcare Conference13 Jan 2026